GSK/Otsuka settle Raxar dispute
Executive Summary
GlaxoSmithKline agrees to make payment to Otsuka to settle the companies' dispute over 1999 withdrawal of the antibiotic Raxar. Otsuka initiated arbitration proceedings in December 2001, arguing that the withdrawal constituted material breach of contract. Glaxo withdrew Raxar due to cardiovascular safety concerns (1"The Pink Sheet" Nov. 1, 1999, p. 17)...
You may also be interested in...
Glaxo Withdraws Raxar Following Seven Fatal Cardiovascular AEs
Glaxo Wellcome is withdrawing the quinolone antibiotic Raxar (grepafloxacin) from the worldwide markets after receiving a total of seven reports of cardiovascular event-related fatalities associated with use of the drug.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.